Challenge
An emerging biotech company was developing a novel asset that would target multiple sub-indications of a rare disease. The client wanted to conduct a commercial assessment and understand the best path forward in sequencing and pricing the product to maximize revenue.
Approach
We executed a rigorous commercial assessment involving a situational review, SoC analysis, pricing research, and structured interviews to quantify opportunity. Clinician and payer perspectives, pricing analogs, and sequencing scenarios were used to define pricing strategies and generate a patient-level revenue model. Outputs informed optimal development sequencing, pricing, and market access while managing execution risk.
Impact
Client adopted the proposed sequencing and pricing approach to lead their clinical trial development efforts and go-to-market strategy.
